Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis

Tuberculosis

Volumn 106, Issue , 2017, Pages 38-43

  Petruccioli, E ^a   Vanini, V ^a   Chiacchio, T ^a   Cuzzi, G ^a   Cirillo, D M ^b   Palmieri, F ^a   Ippolito, G ^a   Goletti, D ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Diagnosis; Latency; Quantiferon; Quantiferon plus; Tuberculosis

Indexed keywords

GAMMA INTERFERON; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BIOLOGICAL MARKER; CFP-10 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; ESAT-6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; IFNG PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ADULT; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; BACTERIAL LOAD; CASE CONTROL STUDY; EVALUATION STUDY; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BACTERIAL PROTEINS; BIOMARKERS; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 85021651983     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2017.06.002     Document Type: Article

References (36)

1. WHO, Global tuberculosis report 2016. WHO Global TB Report 2016, 2016 http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1.
2. Trauer, J.M., Moyo, N., Tay, E.L., Dale, K., Ragonnet, R., McBryde, E.S., et al. Risk of active tuberculosis in the five years following infection… 15%?. Chest 149:2 (2016 Feb), 516–525.
3. Houben, R.M., Dodd, P.J., The global burden of latent tuberculosis infection: a Re-estimation using mathematical modelling. PLoS Med, 13(10), 2016 Oct 25, e1002152.
4. Rangaka, M.X., Wilkinson, K.A., Glynn, J.R., Ling, D., Menzies, D., Mwansa-Kambafwile, J., et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12:1 (2012 Jan), 45–55.
5. Lonnroth, K., Migliori, G.B., Abubakar, I., D'Ambrosio, L., de Vries, G., Diel, R., et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 45:4 (2015 Apr), 928–952.
6. Goletti, D., Sanduzzi, A., Delogu, G., Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 91 (2014 May), 24–31.
7. Getahun, H., Gunneberg, C., Granich, R., Nunn, P., HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 50:Suppl 3 (2010 May 15), S201–S207.
8. Getahun, H., Matteelli, A., Abubakar, I., Aziz, M.A., Baddeley, A., Barreira, D., et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 46:6 (2015 Dec), 1563–1576.
9. Goletti, D., Petruccioli, E., Joosten, S.A., Ottenhoff, T.H., Tuberculosis biomarkers: from diagnosis to protection. Infect Dis Rep, 8(2), 2016 Jun 24, 6568.
10. Petruccioli, E., Scriba, T.J., Petrone, L., Hatherill, M., Cirillo, D.M., Joosten, S.A., et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 48:6 (2016 Dec), 1751–1763.
11. Santin, M., Munoz, L., Rigau, D., Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One, 7(3), 2012, e32482.
12. Vincenti, D., Carrara, S., Butera, O., Bizzoni, F., Casetti, R., Girardi, E., et al. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol 150:1 (2007 Oct), 91–98.
13. Delogu, G., Vanini, V., Cuzzi, G., Chiacchio, T., De Maio, F., Battah, B., et al. Lack of response to HBHA in HIV-infected patients with latent tuberculosis infection. Scand J Immunol 84:6 (2016 Dec), 344–352.
14. Sester, M., van Leth, F., Bruchfeld, J., Bumbacea, D., Cirillo, D.M., Dilektasli, A.G., et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 190:10 (2014 Nov 15), 1168–1176.
15. Day, C.L., Abrahams, D.A., Lerumo, L., Janse van Rensburg, E., Stone, L., O'rie, T., et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 187:5 (2011 Sep 1), 2222–2232.
16. Barcellini, L., Borroni, E., Brown, J., Brunetti, E., Campisi, D., Castellotti, P.F., et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J 48 (2016 Nov), 1411–1419.
17. Barcellini, L., Borroni, E., Brown, J., Brunetti, E., Codecasa, L., Cugnata, F., et al. First independent evaluation of QuantiFERON-TB Plus performance. Eur Respir J 47 (2016 May), 1587–1590.
18. Hoffmann, H., Avsar, K., Gores, R., Mavi, S.C., Hofmann-Thiel, S., Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clin Microbiol Infect 22:8 (2016 Aug), 701–703.
19. Knierer, J., Gallegos Morales, E.N., Schablon, A., Nienhaus, A., Kersten, J.F., QFT-Plus: a plus in variability? - Evaluation of new generation IGRA in serial testing of students with a migration background in Germany. J Occup Med Toxicol, 12, 2017 Jan 5 1–016-0148-z. eCollection 2017.
20. Cirillo, D.M., Barcellini, L., Goletti, D., Preliminary data on precision of QuantiFERON-TB Plus performance. Eur Respir J 48:3 (2016 Sep), 955–956.
21. Gallagher, D., Manissero, D., Stocking, C., Pyne, C., Preliminary data on precision of QuantiFERON-TB Plus performance. Eur Respir J 48:3 (2016 Sep), 953–954.
22. ®-TB Gold Plus, ELISA Package Insert, QUIAGEN. http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf.
23. Yi, L., Sasaki, Y., Nagai, H., Ishikawa, S., Takamori, M., Sakashita, K., et al. Evaluation of QuantiFERON-TB gold plus for detection of Mycobacterium tuberculosis infection in Japan. Sci Rep, 6, 2016 Jul 29, 30617.
24. Pai, M., Zwerling, A., Menzies, D., Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:3 (2008 Aug 5), 177–184.
25. Vanini, V., Petruccioli, E., Gioia, C., Cuzzi, G., Orchi, N., Rianda, A., et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 65:1 (2012 Jul), 49–59.
26. Petruccioli, E., Chiacchio, T., Pepponi, I., Vanini, V., Urso, R., Cuzzi, G., et al. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB plus. J Infect 73:6 (2016 Dec), 588–597.
27. Stenger, S., Hanson, D.A., Teitelbaum, R., Dewan, P., Niazi, K.R., Froelich, C.J., et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282:5386 (1998 Oct 2), 121–125.
28. Chiacchio, T., Petruccioli, E., Vanini, V., Butera, O., Cuzzi, G., Petrone, L., et al. Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS One, 6(11), 2011, e27539.
29. Jafari, C., Thijsen, S., Sotgiu, G., Goletti, D., Dominguez Benitez, J.A., Losi, M., et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med 180:7 (2009 Oct 1), 666–673.
30. ®-TB Gold Plus assay in Zambian adults with active tuberculosis. Int J Tuberc Lung Dis 21:6 (2017 Jun 1), 690–696.
31. Raby, E., Moyo, M., Devendra, A., Banda, J., De Haas, P., Ayles, H., et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One, 3(6), 2008 Jun 18, e2489.
32. Goletti, D., Parracino, M.P., Butera, O., Bizzoni, F., Casetti, R., Dainotto, D., et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res, 8, 2007 Jan 27, 5.
33. Carrara, S., Vincenti, D., Petrosillo, N., Amicosante, M., Girardi, E., Goletti, D., Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 38:5 (2004 Mar 1), 754–756.
34. Kabeer, B.S., Raja, A., Raman, B., Thangaraj, S., Leportier, M., Ippolito, G., et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis, 11, 2011 May 19 135–2334-11-135.
35. Vincenti, D., Carrara, S., De Mori, P., Pucillo, L.P., Petrosillo, N., Palmieri, F., et al. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol Med 9:3–4 (2003 Mar-Apr), 105–111.
36. ® Gold Plus as a potential tuberculosis treatment monitoring tool. Eur Respir J, 49(3), 2017 Mar 22.